Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 28;321(20):2018-2019.
doi: 10.1001/jama.2019.4595.

Cervical Cancer Screening: More Choices in 2019

George F Sawaya  1   2 , Karen Smith-McCune  1 , Miriam Kuppermann  1
Affiliations
Review

Cervical Cancer Screening: More Choices in 2019

George F Sawaya et al. JAMA. .
No abstract available

PubMed Disclaimer

Figures

Figure.
Figure.. Clinical Response to Common Abnormal Screening Test Results for Women at Average Risk of Cervical Cancer, Aged 25 to 65 Years
Clinical responses are based on recommendations by the American College of Obstetricians and Gynecologists, the American Society of Colposcopy and Cervical Pathology, and the Society of Gynecologic Oncology. Average risk indicates women with no prior diagnosis of cervical intraepithelial neoplasia grade 2 or grade 3, adenocarcinoma in situ (AIS) or cervical cancer, women who are not immunocompromised, and women with no in utero exposure to diethylstilbestrol. For women aged 21 to 24 years, colposcopy is recommended for cytology interpreted as high-grade squamous intraepithelial lesion (HSIL) or worse (indicates atypical glandular cells, AIS, carcinoma, or HSIL) or atypical squamous cells, cannot exclude HSIL (ASC-H). For those with atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL), repeat cytology at 12 and 24 months is recommended and colposcopy performed if either is ASC-H, HSIL or worse, or if cytology is persistently abnormal at 24 months. LSIL or worse indicates HSIL or worse in addition to LSIL. HPV indicates human papillomavirus; hrHPV, high-risk human papillomavirus. a Precise test(s) not specified.
See this image and copyright information in PMC

References

    1. American Cancer Society. Cancer facts & figures 2018. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-.... Accessed March 20, 2019.
    1. Agency for Healthcare Research and Quality. Evidence synthesis No. 158: screening for cervical cancer with high-risk human papillomavirus testing: a systematic evidence review for the US Preventive Services Task Force. https://www.uspreventiveservicestaskforce.org/Home/GetFileBylD/3279. Accessed April 13, 2019. - PubMed
    1. Curry SJ, Krist AH, Owens DK, et al.; US Preventive Services Task Force. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018:320(7): 674–686. doi:10.1001/jama.2018.10897 - DOI - PubMed
    1. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol. 2015;125(2):330–337. doi:10.1097/A0G.0000000000000669 - DOI - PubMed
    1. Practice bulletin No. 168 summary: cervical cancer screening and prevention. Obstet Gynecol. 2016;128(4):923–925.doi:10.1097/A0G.0000000000001699 - DOI - PubMed